{"transactions":[{"id":787974,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-08T16:55:26.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":1412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2027 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on May 6, 2026 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":26383,"source":{"system":"sec-edgar","filing":"0001101302-26-000114","document":"wk-form4_1778259322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130226000114/wk-form4_1778259322.xml","form_type":"4"}},{"id":12491,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:10.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":16309,"price":232.08,"value":3784992.72,"ownership":{"direct":true},"balance_after":197794,"source":{"system":"sec-edgar","filing":"0001563545-26-000004","document":"form4-03032026_060307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000004/form4-03032026_060307.xml","form_type":"4"}},{"id":13270,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":20312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029."}],"balance_after":20312,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":20312},"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13269,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":214103,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13268,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":7074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":207465,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13267,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":200391,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13266,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":17041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":194333,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":20800,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":false,"shares":42370,"price":54.86,"value":2324418.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019."}],"balance_after":0,"derivative":{"exercise_price":54.86,"expiration_date":"2026-02-17","underlying":"Common Stock","underlying_shares":42370},"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":20799,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":42370,"price":198.42,"value":8407055.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":177292,"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":20798,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":true,"shares":42370,"price":54.86,"value":2324418.2,"ownership":{"direct":true},"balance_after":219662,"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":1166071,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-25T17:11:08.000Z","date":"2025-04-23","kind":"grant","planned":false,"acquired":true,"shares":2897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2026 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on April 23, 2025 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":24971,"source":{"system":"sec-edgar","filing":"0001101302-25-000050","document":"wk-form4_1745601061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130225000050/wk-form4_1745601061.xml","form_type":"4"}},{"id":26185,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-03-04T22:00:18.000Z","date":"2025-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":17056,"price":205.02,"value":3496821.12,"ownership":{"direct":true},"balance_after":177292,"source":{"system":"sec-edgar","filing":"0001415889-25-006581","document":"form4-03042025_050309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925006581/form4-03042025_050309.xml","form_type":"4"}},{"id":28016,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2025-02-18T22:00:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028."}],"balance_after":25000,"derivative":{"exercise_price":192.86,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-004460","document":"form4-02182025_050212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004460/form4-02182025_050212.xml","form_type":"4"}},{"id":28015,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":7074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":232846,"source":{"system":"sec-edgar","filing":"0001415889-25-004460","document":"form4-02182025_050212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004460/form4-02182025_050212.xml","form_type":"4"}},{"id":28014,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":6060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":225772,"source":{"system":"sec-edgar","filing":"0001415889-25-004460","document":"form4-02182025_050212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004460/form4-02182025_050212.xml","form_type":"4"}},{"id":28013,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":7378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":219712,"source":{"system":"sec-edgar","filing":"0001415889-25-004460","document":"form4-02182025_050212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004460/form4-02182025_050212.xml","form_type":"4"}},{"id":28012,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":17986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":212334,"source":{"system":"sec-edgar","filing":"0001415889-25-004460","document":"form4-02182025_050212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004460/form4-02182025_050212.xml","form_type":"4"}},{"id":35142,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-09-30T21:06:50.000Z","date":"2024-09-24","kind":"gift","planned":false,"acquired":false,"shares":25630,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":194348,"source":{"system":"sec-edgar","filing":"0001415889-24-024096","document":"form4-09302024_090946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924024096/form4-09302024_090946.xml","form_type":"4"}},{"id":1535870,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T17:45:20.000Z","date":"2024-04-24","kind":"grant","planned":false,"acquired":true,"shares":1643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2025 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on April 24, 2024 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":22074,"source":{"system":"sec-edgar","filing":"0001101302-24-000033","document":"wk-form4_1714067112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130224000033/wk-form4_1714067112.xml","form_type":"4"}},{"id":44465,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T22:50:27.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":23966,"price":178.99,"value":4289674.34,"ownership":{"direct":true},"balance_after":219978,"source":{"system":"sec-edgar","filing":"0001415889-24-006160","document":"form4-03012024_050313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924006160/form4-03012024_050313.xml","form_type":"4"}},{"id":44924,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2024-02-23T22:00:23.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":false,"shares":52870,"price":58.88,"value":3112985.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":58.88,"exercise_date":"2016-02-19","expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":52870},"source":{"system":"sec-edgar","filing":"0001415889-24-005065","document":"form4-02232024_050201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924005065/form4-02232024_050201.xml","form_type":"4"}},{"id":44923,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-23T22:00:23.000Z","date":"2024-02-21","kind":"sale","planned":false,"acquired":false,"shares":52870,"price":173.71,"value":9184047.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.51 to $174.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":243944,"source":{"system":"sec-edgar","filing":"0001415889-24-005065","document":"form4-02232024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924005065/form4-02232024_050201.xml","form_type":"4"}},{"id":44922,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-23T22:00:23.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":true,"shares":52870,"price":58.88,"value":3112985.6,"ownership":{"direct":true},"balance_after":296814,"source":{"system":"sec-edgar","filing":"0001415889-24-005065","document":"form4-02232024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924005065/form4-02232024_050201.xml","form_type":"4"}},{"id":45412,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2024-02-20T22:23:26.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":29313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,771 on February 15, 2025, 9,771 on February 15, 2026, and 9,771 on February 15, 2027."}],"balance_after":29313,"derivative":{"exercise_price":0,"exercise_date":"2025-02-15","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":29313},"source":{"system":"sec-edgar","filing":"0001415889-24-004426","document":"form4-02202024_050201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004426/form4-02202024_050201.xml","form_type":"4"}},{"id":45411,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:23:26.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":6060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":243944,"source":{"system":"sec-edgar","filing":"0001415889-24-004426","document":"form4-02202024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004426/form4-02202024_050201.xml","form_type":"4"}},{"id":45410,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:23:26.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":7380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":237884,"source":{"system":"sec-edgar","filing":"0001415889-24-004426","document":"form4-02202024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004426/form4-02202024_050201.xml","form_type":"4"}},{"id":45409,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:23:26.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":8558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":230504,"source":{"system":"sec-edgar","filing":"0001415889-24-004426","document":"form4-02202024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004426/form4-02202024_050201.xml","form_type":"4"}},{"id":45408,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:23:26.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":32097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":221946,"source":{"system":"sec-edgar","filing":"0001415889-24-004426","document":"form4-02202024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004426/form4-02202024_050201.xml","form_type":"4"}},{"id":1911905,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-28T20:02:55.000Z","date":"2023-04-26","kind":"grant","planned":false,"acquired":true,"shares":2849,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2024 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on April 26, 2023 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":20431,"source":{"system":"sec-edgar","filing":"0001101302-23-000061","document":"wf-form4_168271215900242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130223000061/wf-form4_168271215900242.xml","form_type":"4"}},{"id":57881,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Option (Right to Buy)","published_at":"2023-03-02T22:01:49.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":26990,"price":51.42,"value":1387825.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":51.42,"exercise_date":"2015-02-20","expiration_date":"2024-02-19","underlying":"Common Stock","underlying_shares":26990},"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":57880,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:01:49.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":780,"price":153.39,"value":119644.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $153.47, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":189849,"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":57879,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:01:49.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":9220,"price":153.05,"value":1411121.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":190629,"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":57878,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:01:49.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":26990,"price":155,"value":4183450.0,"ownership":{"direct":true},"balance_after":199849,"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":57877,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:01:49.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":26990,"price":51.42,"value":1387825.8,"ownership":{"direct":true},"balance_after":226839,"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":57876,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:01:49.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":33359,"price":154.28,"value":5146626.52,"ownership":{"direct":true},"balance_after":199849,"source":{"system":"sec-edgar","filing":"0001415889-23-003851","document":"form4-03022023_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003851/form4-03022023_100335.xml","form_type":"4"}},{"id":58453,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":25000,"price":51.42,"value":1285500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F10","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":51.42,"exercise_date":"2015-02-20","expiration_date":"2024-02-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58452,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":22957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F9","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,653 on February 16, 2024, 7,652 on February 16, 2025, and 7,652 on February 16, 2026."}],"balance_after":22957,"derivative":{"exercise_price":149.62,"exercise_date":"2024-02-16","expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":22957},"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58451,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":10754,"price":150.05,"value":1613637.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.71 to $150.05 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":233208,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58450,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":14246,"price":149.13,"value":2124505.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.69 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":243962,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58449,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":25000,"price":51.42,"value":1285500.0,"ownership":{"direct":true},"balance_after":258208,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58448,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":7380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":233208,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58447,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":8560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":225828,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58446,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":11229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":217268,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":58445,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, OPERATIONS"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:13:12.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":48127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date\nreported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":206039,"source":{"system":"sec-edgar","filing":"0001415889-23-002945","document":"form4-02212023_110202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002945/form4-02212023_110202.xml","form_type":"4"}},{"id":2288465,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:16:36.000Z","date":"2022-04-27","kind":"grant","acquired":true,"shares":1849,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were awarded on April 27, 2022 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2023 Annual Meeting of Stockholders."}],"balance_after":17582,"source":{"system":"sec-edgar","filing":"0001101302-22-000030","document":"wf-form4_165126332100129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130222000030/wf-form4_165126332100129.xml","form_type":"4"}},{"id":69867,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T23:08:23.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":22108,"price":149.54,"value":3306030.32,"ownership":{"direct":true},"balance_after":157912,"source":{"system":"sec-edgar","filing":"0001179110-22-001830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001830/edgar.xml","form_type":"4"}},{"id":70229,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (Right to Buy)","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":35026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F8","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025."}],"balance_after":35026,"derivative":{"exercise_price":144.54,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":35026},"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":70228,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":13837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date."}],"balance_after":180020,"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":70227,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":7490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":166183,"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":70226,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":11229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":158693,"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":70225,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":5568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":147464,"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":70224,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:40:52.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":25612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":141896,"source":{"system":"sec-edgar","filing":"0001179110-22-001517","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001517/edgar.xml","form_type":"4"}},{"id":86750,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (Right to buy)","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":74520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":35.88,"exercise_date":"2014-02-14","expiration_date":"2023-02-13","underlying":"Common Stock","underlying_shares":74520},"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":86749,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (Right to buy)","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":12400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":29.23,"exercise_date":"2013-02-17","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":12400},"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":86748,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":9057,"price":116.7049,"value":1056996.2793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":116284,"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":86747,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":77863,"price":116.2431,"value":9051036.4953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":125341,"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":86746,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":74520,"price":35.88,"value":2673777.6,"ownership":{"direct":true},"balance_after":203204,"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":86745,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-05-26T21:20:36.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":12400,"price":29.23,"value":362452.0,"ownership":{"direct":true},"balance_after":128684,"source":{"system":"sec-edgar","filing":"0001179110-21-005980","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021005980/edgar.xml","form_type":"4"}},{"id":2733898,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-03T20:12:59.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":1610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2022 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on April 29, 2021 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":15733,"source":{"system":"sec-edgar","filing":"0001101302-21-000048","document":"wf-form4_162007276626333.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130221000048/wf-form4_162007276626333.xml","form_type":"4"}},{"id":92085,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-03T01:31:44.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":15785,"price":107.74,"value":1700675.9,"ownership":{"direct":true},"balance_after":116284,"source":{"system":"sec-edgar","filing":"0001179110-21-002605","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002605/edgar.xml","form_type":"4"}},{"id":92741,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option(right to buy)","published_at":"2021-02-22T23:23:25.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":42236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,079 on February 18, 2022, 14,079 on February 18, 2023, and 14,078 on February 18, 2024."}],"balance_after":42236,"derivative":{"exercise_price":105.92,"exercise_date":"2022-02-18","expiration_date":"2031-02-17","underlying":"Common stock","underlying_shares":42236},"source":{"system":"sec-edgar","filing":"0001179110-21-002050","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002050/edgar.xml","form_type":"4"}},{"id":92740,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:23:25.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":11229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":132069,"source":{"system":"sec-edgar","filing":"0001179110-21-002050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002050/edgar.xml","form_type":"4"}},{"id":92739,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:23:25.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":5568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":120840,"source":{"system":"sec-edgar","filing":"0001179110-21-002050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002050/edgar.xml","form_type":"4"}},{"id":92738,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:23:25.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":4279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":115272,"source":{"system":"sec-edgar","filing":"0001179110-21-002050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002050/edgar.xml","form_type":"4"}},{"id":92737,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:23:25.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":14552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":110993,"source":{"system":"sec-edgar","filing":"0001179110-21-002050","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002050/edgar.xml","form_type":"4"}},{"id":98749,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-12T22:56:51.000Z","date":"2020-11-10","kind":"sale","acquired":false,"shares":17426,"price":98,"value":1707748.0,"ownership":{"direct":true},"balance_after":96441,"source":{"system":"sec-edgar","filing":"0001179110-20-011059","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020011059/edgar.xml","form_type":"4"}},{"id":98753,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (Right to buy)","published_at":"2020-11-12T22:55:54.000Z","date":"2020-11-04","kind":"exercise","acquired":false,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":24.2082,"exercise_date":"2012-02-18","expiration_date":"2021-02-17","underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001179110-20-011058","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020011058/edgar.xml","form_type":"4/A","original_submission_date":"2020-11-06"}},{"id":98752,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-12T22:55:54.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":4800,"price":93.61,"value":449328.0,"ownership":{"direct":true},"balance_after":113867,"source":{"system":"sec-edgar","filing":"0001179110-20-011058","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020011058/edgar.xml","form_type":"4/A","original_submission_date":"2020-11-06"}},{"id":98751,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-12T22:55:54.000Z","date":"2020-11-04","kind":"exercise","acquired":true,"shares":4800,"price":24.2082,"value":116199.36,"ownership":{"direct":true},"balance_after":118667,"source":{"system":"sec-edgar","filing":"0001179110-20-011058","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020011058/edgar.xml","form_type":"4/A","original_submission_date":"2020-11-06"}},{"id":99099,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-06T21:29:05.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":4800,"price":93.61,"value":449328.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a previously adopted plan complying with Rule 10b5-1(c)."}],"balance_after":109067,"source":{"system":"sec-edgar","filing":"0001179110-20-010867","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020010867/edgar.xml","form_type":"4"}},{"id":3166111,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T20:29:08.000Z","date":"2020-04-29","kind":"grant","acquired":true,"shares":2567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2021 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on April 29, 2020 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":14123,"source":{"system":"sec-edgar","filing":"0001101302-20-000034","document":"wf-form4_158836493131363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130220000034/wf-form4_158836493131363.xml","form_type":"4"}},{"id":106570,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-03T21:56:04.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":16342,"price":85.42,"value":1395933.64,"ownership":{"direct":true},"balance_after":113867,"source":{"system":"sec-edgar","filing":"0001179110-20-002861","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002861/edgar.xml","form_type":"4"}},{"id":107165,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (right to buy)","published_at":"2020-02-24T23:00:47.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":73649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,550 on February 20, 2021, 24,550 on February 20, 2022, and 24,549 on February 20, 2023."}],"balance_after":73649,"derivative":{"exercise_price":93.5,"exercise_date":"2021-02-20","expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":73649},"source":{"system":"sec-edgar","filing":"0001179110-20-002131","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002131/edgar.xml","form_type":"4"}},{"id":107164,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:00:47.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":5568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":130209,"source":{"system":"sec-edgar","filing":"0001179110-20-002131","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002131/edgar.xml","form_type":"4"}},{"id":107163,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:00:47.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":4279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":124641,"source":{"system":"sec-edgar","filing":"0001179110-20-002131","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002131/edgar.xml","form_type":"4"}},{"id":107162,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:00:47.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":7170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":120362,"source":{"system":"sec-edgar","filing":"0001179110-20-002131","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002131/edgar.xml","form_type":"4"}},{"id":107161,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:00:47.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":19880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":113192,"source":{"system":"sec-edgar","filing":"0001179110-20-002131","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002131/edgar.xml","form_type":"4"}},{"id":3541392,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-03T20:05:18.000Z","date":"2019-05-01","kind":"grant","acquired":true,"shares":3569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2020 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on May 1, 2019 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":11556,"source":{"system":"sec-edgar","filing":"0001101302-19-000021","document":"wf-form4_155691390349252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130219000021/wf-form4_155691390349252.xml","form_type":"4"}},{"id":118720,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-03-06T22:03:03.000Z","date":"2019-03-05","kind":"sale","acquired":false,"shares":15797,"price":79.0327,"value":1248479.5619,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.77 to $79.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":93312,"source":{"system":"sec-edgar","filing":"0001179110-19-003445","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019003445/edgar.xml","form_type":"4"}},{"id":118967,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-03-04T21:58:00.000Z","date":"2019-02-28","kind":"tax_withholding","acquired":false,"shares":12569,"price":79.41,"value":998104.29,"ownership":{"direct":true},"balance_after":109109,"source":{"system":"sec-edgar","filing":"0001179110-19-003089","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019003089/edgar.xml","form_type":"4"}},{"id":119495,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Option (Right to buy)","published_at":"2019-02-22T22:18:51.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":34267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,423 on February 21, 2020, 11,422 on February 21, 2021, and 11,422 on February 21, 2022."}],"balance_after":34267,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":34267},"source":{"system":"sec-edgar","filing":"0001179110-19-002365","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002365/edgar.xml","form_type":"4"}},{"id":119494,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:18:51.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":4281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":121678,"source":{"system":"sec-edgar","filing":"0001179110-19-002365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002365/edgar.xml","form_type":"4"}},{"id":119493,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:18:51.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":7170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":117397,"source":{"system":"sec-edgar","filing":"0001179110-19-002365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002365/edgar.xml","form_type":"4"}},{"id":119492,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:18:51.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":7080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":110227,"source":{"system":"sec-edgar","filing":"0001179110-19-002365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002365/edgar.xml","form_type":"4"}},{"id":119491,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:18:51.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":9835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":103147,"source":{"system":"sec-edgar","filing":"0001179110-19-002365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002365/edgar.xml","form_type":"4"}},{"id":3940179,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-10T20:55:57.000Z","date":"2018-05-09","kind":"grant","acquired":true,"shares":4090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2019 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on May 9, 2018 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":7987,"source":{"system":"sec-edgar","filing":"0001101302-18-000026","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130218000026/edgar.xml","form_type":"4"}},{"id":131343,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:31:12.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":1337,"price":117.7695,"value":157457.8215,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.74 to $117.792, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":93312,"source":{"system":"sec-edgar","filing":"0001179110-18-003339","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018003339/edgar.xml","form_type":"4"}},{"id":131342,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:31:12.000Z","date":"2018-02-28","kind":"tax_withholding","acquired":false,"shares":12683,"price":118.26,"value":1499891.58,"ownership":{"direct":true},"balance_after":94649,"source":{"system":"sec-edgar","filing":"0001179110-18-003339","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018003339/edgar.xml","form_type":"4"}},{"id":132330,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Option (right to buy)","published_at":"2018-02-16T22:51:19.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":23160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,720 on February 15, 2019, 7,720 on February 15, 2020, and 7,720 on February 15, 2021."}],"balance_after":23160,"derivative":{"exercise_price":114.36,"exercise_date":"2019-02-15","expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":23160},"source":{"system":"sec-edgar","filing":"0001179110-18-002295","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018002295/edgar.xml","form_type":"4"}},{"id":132329,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:51:19.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":7170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":107332,"source":{"system":"sec-edgar","filing":"0001179110-18-002295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018002295/edgar.xml","form_type":"4"}},{"id":132328,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:51:19.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":8283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":100162,"source":{"system":"sec-edgar","filing":"0001179110-18-002295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018002295/edgar.xml","form_type":"4"}},{"id":132327,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:51:19.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":7080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":91879,"source":{"system":"sec-edgar","filing":"0001179110-18-002295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911018002295/edgar.xml","form_type":"4"}},{"id":137180,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Option (right to buy)","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"exercise","acquired":false,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":24.2082,"exercise_date":"2014-02-18","expiration_date":"2021-02-17","underlying":"Common stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137179,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"sale","acquired":false,"shares":2338,"price":85.06,"value":198870.28,"ownership":{"direct":true},"balance_after":84799,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137178,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"sale","acquired":false,"shares":1030,"price":85.04,"value":87591.2,"ownership":{"direct":true},"balance_after":87137,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137177,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"sale","acquired":false,"shares":132,"price":85.03,"value":11223.96,"ownership":{"direct":true},"balance_after":88167,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137176,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"sale","acquired":false,"shares":3600,"price":84.995,"value":305982.0,"ownership":{"direct":true},"balance_after":88299,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137175,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"sale","acquired":false,"shares":1200,"price":84.99,"value":101988.0,"ownership":{"direct":true},"balance_after":91899,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":137174,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-12T21:40:26.000Z","date":"2017-09-11","kind":"exercise","acquired":true,"shares":4800,"price":24.2082,"value":116199.36,"ownership":{"direct":true},"balance_after":93099,"source":{"system":"sec-edgar","filing":"0001179110-17-012208","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911017012208/edgar.xml","form_type":"4"}},{"id":4234759,"issuer":{"id":3271,"kind":"organization","name":"ENTEGRIS INC"},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-15T21:03:52.000Z","date":"2017-08-14","kind":"grant","acquired":true,"shares":3897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2018 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were awarded on August 14, 2017 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan which provides for the award of Restricted Stock Units to independent directors in consideration for services as such."}],"balance_after":3897,"source":{"system":"sec-edgar","filing":"0001101302-17-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101302/000110130217000030/edgar.xml","form_type":"4"}}],"next_cursor":"2017-08-15T21:03:52.000000Z,4234759"}